Japanese authorities approve fourth indication for Genentech-Novartis' eye drug Lucentis

The Japanese regulatory bodies have approved Lucentis (ranibizumab) for a fourth indication for treatment of patients with diabetic macular edema (DME), a major cause of vision loss among diabetic patients.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news